Loading...
•
Dec 31, 2024
Cardiff Oncology Q4 2024 Earnings Report
Cardiff Oncology reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting positive clinical data and a strengthened financial position.
Key Takeaways
Cardiff Oncology announced positive initial data from its ongoing first-line RAS-mutated mCRC clinical trial (CRDF-004), with a 64% objective response rate in the 30mg onvansertib dose arm. The company also raised $40 million in an oversubscribed offering, strengthening its cash position to $91.7 million, projected to fund operations into Q1 2027.
Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut mCRC clinical trial (CRDF-004).
Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors.
Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC.
Cash and equivalents of $91.7 million as of December 31, 2024, projected runway into Q1 2027.
Revenue by Segment
Forward Guidance
Cardiff Oncology anticipates sharing additional clinical updates from the CRDF-004 trial in the first half of 2025 and believes its current cash resources are sufficient to fund operations into Q1 2027.
Positive Outlook
- Additional clinical data from CRDF-004 trial expected in 1H 2025.
- Current cash resources are sufficient to fund operations into Q1 2027.
- Positive initial data from ongoing first-line RAS-mutated mCRC clinical trial (CRDF-004).
- Onvansertib demonstrated a higher ORR and deeper tumor regression at the 30mg dose compared to the 20mg dose.
- Onvansertib was well tolerated at both doses in the CRDF-004 trial.
Challenges Ahead
- Clinical trials involve a lengthy and expensive process with an uncertain outcome.
- Results of earlier studies and trials may not be predictive of future trial results.
- Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...